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Bovine leukemia virus (BLV) is an oncogenic retrovi-
rus that infects cattle. It is classified in the human T-cell 
leukemia virus (HTLV) group, although BLV mainly 
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infects B cells rather than T cells. Most BLV-infected 
cattle remain asymptomatic, but about 30% develop 
persistent lymphocytosis, and perhaps 5% eventually 
acquire B-cell lymphoma. Mainly as a result of the lat-
ter condition, BLV is a significant economic problem 
for cattle producers worldwide. Moreover, because of 
the close genetic similarities between the two virus-
es, BLV may also be a useful model for investigating 
HTLV-associated diseases in humans. The prognosis 
of HTLV-I-associated disease is generally poor because 
of resistance to chemotherapy. Clinical trials using an-
tiretroviral agents to treat HTLV-I-infected patients 
have been generally unsuccessful; there is clearly a 
need for additional therapies.
We are currently using an in vitro BLV infection assay 
as a model to screen various compounds for antiviral 
activity. Persistently BLV-infected fetal lamb kidney 
(FLK) cells are used as a source for infection of other 
cell types. For example, feline CC81 cells form multi-
nucleated syncytia upon exposure to FLK-BLV cells. 
The formation of syncytia can be quantitated to reflect 
the levels of infection. We recently found that the BLV-
induced syncytium formation can be inhibited by riba-
virin or alpha interferon, but a combination of ribavi-
rin and alpha interferon at doses similar to those used 
to treat human hepatitis C virus infection are much 
more effective. No cytotoxic effects were observed at 
the effective doses, and this inhibition is greater than 
that achievable with either drug separately. We are 
currently refining our infection assay as well as testing 
additional compounds. Furthermore, we are develop-
ing additional methods to quantitate the production of 
BLV antigen, as well as the expression of BLV-specific 
mRNA, to corroborate these results.
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